Overview

Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Lorazepam
Criteria
Inclusion Criteria:

- Signed informed consent before any study-related procedures start.

- The patient is previously diagnosed with Generalized Anxiety Disorder.

- The patient has a HADS-A (anxiety) score ≥10 at both screening and randomization.

Exclusion Criteria:

- Patient has a lifetime history of schizophrenia or other psychotic disorders

- Patient has a history of seizures or seizure disorder.

- Patient is pregnant or breast feeding.

- Patient has received electroconvulsive treatment (ECT) in the past.